Intranasal respiratory syncytial virus vaccine - Mucosis

Drug Profile

Intranasal respiratory syncytial virus vaccine - Mucosis

Alternative Names: Respiratory Syncytial Virus vaccine - Mucosis; SynGEM; SynGEM prefusion F vaccine - Mucosis

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Imperial College of Science, Technology and Medicine; Mucosis
  • Class Antibodies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Respiratory syncytial virus infections

Most Recent Events

  • 01 Oct 2016 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in United Kingdom (Intranasal) (NCT02958540)
  • 16 May 2013 Preclinical trials in Respiratory syncytial virus infections in Netherlands (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top